US OptionsDetailed Quotes
GMAB250516P15000
- 0.10
- 0.000.00%
15min DelayClose May 1 16:00 ET
0.00High0.00Low
0.10Open0.10Pre Close0 Volume135 Open Interest15.00Strike Price0.00Turnover107.59%IV28.81%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier15DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0488Delta0.0224Gamma209.30Leverage Ratio-0.0150Theta-0.0004Rho-10.22Eff Leverage0.0043Vega
Genmab Stock Discussion
Sign in to post a comment
$Genmab (GMAB.US)$
Breakthrough: New EU-Approved Cancer Drug Cuts Death Risk by 30% - First of its Kind for Cervical Cancer
Breakthrough: New EU-Approved Cancer Drug Cuts Death Risk by 30% - First of its Kind for Cervical Cancer
3
1
$Genmab (GMAB.US)$
Breakthrough: New EU-Approved Cancer Drug Cuts Death Risk by 30% - First of its Kind for Cervical Cancer
Breakthrough: New EU-Approved Cancer Drug Cuts Death Risk by 30% - First of its Kind for Cervical Cancer
1
$Genmab (GMAB.US)$
Breakthrough: New Ovarian Cancer Drug Achieves Remarkable 55% Response Rate in Clinical Trial
Breakthrough: New Ovarian Cancer Drug Achieves Remarkable 55% Response Rate in Clinical Trial
$Genmab (GMAB.US)$
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38
$Genmab (GMAB.US)$ can it touch 24? or it will drop more? since opens low today🙄
$Genmab (GMAB.US)$
Breakthrough Lymphoma Drug EPKINLY Scores Dual Approval in Japan: 95% Patient Response
Breakthrough Lymphoma Drug EPKINLY Scores Dual Approval in Japan: 95% Patient Response
1
1
1
No comment yet
Lnova : whoa!